Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01544569|
Recruitment Status : Completed
First Posted : March 6, 2012
Last Update Posted : May 18, 2016
RATIONALE: Studying samples of tissue from patients with rhabdoid tumors in the laboratory may help doctor learn more about changes that occur in DNA and identify genes related to cancer.
PURPOSE: This research trial studies biomarkers in samples from young patients with rhabdoid tumors.
|Condition or disease||Intervention/treatment|
|Kidney Cancer||Genetic: DNA analysis Genetic: fluorescence in situ hybridization Genetic: gene expression analysis Genetic: gene mapping Genetic: microarray analysis Genetic: polymerase chain reaction Genetic: protein expression analysis Other: laboratory biomarker analysis Other: medical chart review|
- To investigate the expression and function of transposons in 50 primary rhabdoid tumors.
OUTLINE: Freshly frozen rhabdoid tumors will be studied using fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR) to establish the genomic location of transposons. Protein expression in rhabdoid tumor tissue microarrays is also analyzed.
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Endogenous DNA Transposition in Rhabdoid Tumors|
|Study Start Date :||March 2012|
|Actual Primary Completion Date :||May 2016|
- Expression and function of transposons in rhabdoid tumors
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01544569
|Principal Investigator:||Elizabeth A. Mullen, MD||Dana-Farber Cancer Institute|